EI

270.8

+1.58%↑

SAN

78.73

-1.04%↓

MRK1

106.5

-0.47%↓

SHL.DE

47.61

-0.48%↓

ARGX

631.8

-0.94%↓

EI

270.8

+1.58%↑

SAN

78.73

-1.04%↓

MRK1

106.5

-0.47%↓

SHL.DE

47.61

-0.48%↓

ARGX

631.8

-0.94%↓

EI

270.8

+1.58%↑

SAN

78.73

-1.04%↓

MRK1

106.5

-0.47%↓

SHL.DE

47.61

-0.48%↓

ARGX

631.8

-0.94%↓

EI

270.8

+1.58%↑

SAN

78.73

-1.04%↓

MRK1

106.5

-0.47%↓

SHL.DE

47.61

-0.48%↓

ARGX

631.8

-0.94%↓

EI

270.8

+1.58%↑

SAN

78.73

-1.04%↓

MRK1

106.5

-0.47%↓

SHL.DE

47.61

-0.48%↓

ARGX

631.8

-0.94%↓

Search

Pharming Group NV

Abrir

1.226 1.57

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.201

Máximo

1.23

Indicadores-chave

By Trading Economics

Rendimento

19M

4.7M

Vendas

14M

93M

EPS

0.006

Margem de lucro

5.035

Funcionários

404

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+102.26% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

233M

850M

Abertura anterior

-0.34

Fecho anterior

1.226

Pharming Group NV Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de set. de 2025, 22:39 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 de set. de 2025, 16:43 UTC

Grandes Movimentos do Mercado

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 de set. de 2025, 16:42 UTC

Grandes Movimentos do Mercado

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 de set. de 2025, 16:35 UTC

Grandes Movimentos do Mercado

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 de set. de 2025, 23:46 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de set. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 de set. de 2025, 23:34 UTC

Conversa de Mercado

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 de set. de 2025, 22:48 UTC

Conversa de Mercado

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 de set. de 2025, 22:12 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL Expects Commercial Launch in 2029

15 de set. de 2025, 22:12 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 de set. de 2025, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 de set. de 2025, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 de set. de 2025, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 de set. de 2025, 21:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 de set. de 2025, 21:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 de set. de 2025, 21:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 de set. de 2025, 21:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 de set. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de set. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

15 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

15 de set. de 2025, 19:29 UTC

Conversa de Mercado

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 de set. de 2025, 19:14 UTC

Conversa de Mercado

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 de set. de 2025, 18:16 UTC

Conversa de Mercado

Gold Powers to New High -- Market Talk

15 de set. de 2025, 18:05 UTC

Conversa de Mercado

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 de set. de 2025, 17:50 UTC

Aquisições, Fusões, Aquisições de Empresas

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 de set. de 2025, 17:10 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de set. de 2025, 17:10 UTC

Conversa de Mercado

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 de set. de 2025, 16:52 UTC

Conversa de Mercado

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 de set. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

15 de set. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

Comparação entre Pares

Variação de preço

Pharming Group NV Previsão

Preço-alvo

By TipRanks

102.26% parte superior

Previsão para 12 meses

Média 2.447 EUR  102.26%

Máximo 2.45 EUR

Mínimo 2.45 EUR

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Pharming Group NV - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

1

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
help-icon Live chat